Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06646198
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension (DoTH)
Transjugular Intrahepatic Portosystemic Shunt (TIPS) Plus Half-dose Donafenib (a Kind of Anti-angiogenesis Agents) in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension: a Prospective, Single-arm, Phase II Study. (DoTH Study)
Sponsor: Fei Gao
Conditions
Hepatocellular Carcinoma with PVTT
Updated 1 time since 2024 Last updated: Oct 15, 2024 Started: Oct 8, 2024 Primary completion: May 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Hepatocellular Carcinoma with PVTT, this trial is actively recruiting participants. The trial is conducted by Fei Gao and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fei Gao
Data source: Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .